MCID: FST010
MIFTS: 39

Fasting Hypoglycemia

Categories: Rare diseases

Aliases & Classifications for Fasting Hypoglycemia

MalaCards integrated aliases for Fasting Hypoglycemia:

Name: Fasting Hypoglycemia 50 69

Classifications:



Summaries for Fasting Hypoglycemia

MalaCards based summary : Fasting Hypoglycemia is related to glycogen storage disease 0, liver and acyl-coa dehydrogenase, medium chain, deficiency of. An important gene associated with Fasting Hypoglycemia is ACADM (Acyl-CoA Dehydrogenase, C-4 To C-12 Straight Chain), and among its related pathways/superpathways are Regulation of lipid metabolism Insulin signaling-generic cascades and NFAT and Cardiac Hypertrophy. The drugs Metformin and Repaglinide have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and pancreas, and related phenotypes are Increased shRNA abundance (Z-score > 2) and behavior/neurological

Related Diseases for Fasting Hypoglycemia

Diseases related to Fasting Hypoglycemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 76)
id Related Disease Score Top Affiliating Genes
1 glycogen storage disease 0, liver 11.0
2 acyl-coa dehydrogenase, medium chain, deficiency of 10.8
3 glycogen storage disease 0, muscle 10.8
4 phosphoenolpyruvate carboxykinase-1, cytosolic, deficiency 10.8
5 intranuclear rod myopathy 10.6 GYS1 GYS2
6 hypoglycemia 10.5
7 hyperinsulinemic hypoglycemia, familial, 4 10.2 ACADM GLUD1
8 hyperlipoproteinemia, type ib 10.1 IGF1 INSR
9 lacrimal duct obstruction 10.1 IGF1 IGF2
10 glomerulosclerosis, focal segmental, 1 10.1 IGF1 INSR
11 growth hormone insensitivity, partial 10.0 IGF1 IGF2
12 intermittent squint 10.0 CRH POMC
13 renal pelvis carcinoma 10.0 CRH POMC
14 actinobacillosis 10.0 CRH POMC
15 hypodermyasis 10.0 CRH POMC
16 prolactin producing pituitary tumor 9.9 IGF1 POMC
17 insulinoma 9.9
18 algoneurodystrophy 9.9 IGF1 IGF2
19 dressler's syndrome 9.9 CRH POMC
20 autoimmune disease of central nervous system 9.9 CRH POMC
21 hyperinsulinism 9.9
22 growth hormone deficiency 9.9
23 early-onset parkinson disease 9.8 CRH POMC
24 peroneal neuropathy 9.8 GLP1R IGF1 INSR
25 protein s deficiency 9.8 IGF1 POMC
26 hypothyroidism, congenital, nongoitrous 4 9.8 IGF1 POMC
27 immune system organ benign neoplasm 9.8 IGF1 POMC
28 trabecular follicular adenocarcinoma 9.8 CRH POMC
29 osteopetrosis 9.8 CD36 IGF1 IGF2
30 leukemia 9.8
31 lymphoblastic leukemia 9.8
32 hyperglycemia 9.8
33 uterine corpus adenocarcinofibroma 9.8 CRH POMC
34 exostosis 9.7 GLUD1 IGF1 INSR
35 bronchiectasis 9.7 CRH POMC
36 hallux varus and preaxial polysyndactyly 9.7 IGF1 IGF2
37 diabetic cataract 9.7 GLUD1 IGF2 INSR
38 fetal parvovirus syndrome 9.6 IGF1 IGF2 INSR
39 hepatocellular carcinoma 9.6
40 hyperprolactinemia 9.6
41 aromatic l-amino acid decarboxylase deficiency 9.6
42 hyperinsulinism-hyperammonemia syndrome 9.6
43 glycogen storage disease 9.6
44 hepatitis 9.6
45 islet cell tumor 9.6
46 histiocytoma 9.6
47 fibrous histiocytoma 9.6
48 pancreatitis 9.6
49 hyperammonemia 9.6
50 multiple endocrine neoplasia 9.6

Graphical network of the top 20 diseases related to Fasting Hypoglycemia:



Diseases related to Fasting Hypoglycemia

Symptoms & Phenotypes for Fasting Hypoglycemia

GenomeRNAi Phenotypes related to Fasting Hypoglycemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.11 POMC
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.11 IGF1 POMC
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.11 IGF1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.11 IGF2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.11 GYS2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.11 GYS2 POMC
7 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.11 CD36
8 Increased shRNA abundance (Z-score > 2) GR00366-A-131 10.11 GYS2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.11 GYS2 IGF2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.11 IGF1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.11 GYS2 GLP1R
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.11 CD36 GLP1R
13 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.11 GYS2 IGF2 IGF1 GLP1R
14 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.11 GYS2 IGF1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.11 IGF1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.11 IGF2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.11 IGF1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.11 GLP1R
19 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.11 GYS2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.11 GYS2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.11 GYS2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.11 IGF1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.11 IGF1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.11 CD36
25 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.11 IGF1 CD36 POMC
26 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.11 CD36
27 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.11 POMC
28 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.11 CD36
29 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.11 CD36
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.11 GYS2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.11 CD36
32 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.11 IGF2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.11 IGF2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.11 GLP1R
35 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.11 IGF2
36 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.11 IGF2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.11 POMC
38 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.11 POMC
39 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.11 IGF1

MGI Mouse Phenotypes related to Fasting Hypoglycemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.06 CRH GLP1R GYS1 CD36 GYS2 INSR
2 cardiovascular system MP:0005385 10.03 IGF1 IGF2 ACADM GYS1 CD36 GYS2
3 cellular MP:0005384 10.01 CRH IGF1 GYS1 CD36 GYS2 INSR
4 homeostasis/metabolism MP:0005376 10 IGF1 CRH GLP1R IGF2 GLUD1 ACADM
5 endocrine/exocrine gland MP:0005379 9.97 IGF1 CRH GLP1R IGF2 GLUD1 CD36
6 growth/size/body region MP:0005378 9.97 CRH IGF1 GLP1R GLUD1 GYS1 CD36
7 adipose tissue MP:0005375 9.95 CRH IGF1 GLP1R CD36 POMC INSR
8 liver/biliary system MP:0005370 9.76 CRH IGF2 ACADM GYS1 CD36 GYS2
9 muscle MP:0005369 9.5 IGF1 IGF2 ACADM GYS1 CD36 GYS2
10 renal/urinary system MP:0005367 9.1 CRH IGF1 CD36 INSR POMC IGF2

Drugs & Therapeutics for Fasting Hypoglycemia

Drugs for Fasting Hypoglycemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
2
Repaglinide Approved, Investigational Phase 4,Phase 3,Phase 2 135062-02-1 65981
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
4
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1 116094-23-6 16132418
5
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
6
Insulin Detemir Approved Phase 4,Phase 3 169148-63-4 5311023
7
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
8
Gliclazide Approved Phase 4,Phase 3,Phase 2 21187-98-4 3475
9
Glimepiride Approved Phase 4,Phase 3,Phase 2 93479-97-1 3476
10
Glyburide Approved Phase 4,Phase 3,Phase 2 10238-21-8 3488
11
Canagliflozin Approved Phase 4,Phase 2 842133-18-0
12
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
13
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1 160337-95-1
14
Insulin-glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1 207748-29-6
15
Vildagliptin Approved, Investigational Phase 4,Phase 3 274901-16-5 6918537
16
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
17 Racepinephrine Approved Phase 4
18
Liraglutide Approved Phase 4,Phase 2,Phase 3 204656-20-2 44147092
19
Insulin Lispro Approved Phase 4,Phase 3,Phase 2 133107-64-9
20
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
21
Simvastatin Approved Phase 4 79902-63-9 54454
22
Glipizide Approved Phase 4,Phase 3 29094-61-9 3478
23
Pramlintide Approved, Investigational Phase 4,Phase 2 151126-32-8
24
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
25
Gliquidone Approved Phase 4 33342-05-1 91610
26
Saxagliptin Approved Phase 4,Phase 3 361442-04-8 11243969
27
Linagliptin Approved Phase 4,Phase 3 668270-12-0 10096344
28
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
29
Ethanol Approved Phase 4,Phase 2 64-17-5 702
30
Somatostatin Approved Phase 4 38916-34-6, 51110-01-1 53481605
31
Guaifenesin Approved, Vet_approved Phase 4 93-14-1 3516
32 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
33
2,4-thiazolidinedione Investigational Phase 4,Phase 3 2295-31-0
34 Antipsychotic Agents Phase 4
35 Central Nervous System Depressants Phase 4
36 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Psychotropic Drugs Phase 4
38 Tranquilizing Agents Phase 4
39 Cortisol succinate Phase 4
40 glucagon Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Glucagon-Like Peptide 1 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Hydrocortisone 17-butyrate 21-propionate Phase 4
44 Hydrocortisone acetate Phase 4
45 insulin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Insulin degludec, insulin aspart drug combination Phase 4,Phase 3,Phase 1
47 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Insulin, Long-Acting Phase 4,Phase 3,Phase 2,Phase 1
49 Insulin, Isophane Phase 4,Phase 3,Phase 2,Phase 1
50 Isophane insulin, beef Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 311)

id Name Status NCT ID Phase Drugs
1 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
2 A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients Unknown status NCT00336310 Phase 4 Repaglinide
3 Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
4 Making Ramadhan Fasting a Safer Experience With Technology Study Completed NCT02189135 Phase 4
5 Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263) Completed NCT01131182 Phase 4 Sitagliptin phosphate;Comparator: Sulfonylurea;Metformin
6 Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan Completed NCT02941367 Phase 4 Lixisenatide (AVE0010);Sulfonylurea;metformin;basal insulin
7 An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan Completed NCT02737657 Phase 4
8 DOMME Dose Optimization Multicentric Mexican Evaluation Completed NCT00488527 Phase 4 Insulin glargine
9 Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial) Completed NCT00390728 Phase 4 Insulin Glargine
10 Lantus Versus Levemir Treat-To-Target Completed NCT00405418 Phase 4 Insulin glargine;Insulin Detemir
11 Insulin Glargine During and After the Period of Fasting in Ramadan Completed NCT00258804 Phase 4 Insulin glargine
12 A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus Completed NCT00399724 Phase 4 Insulin glargine
13 Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. Completed NCT01122979 Phase 4 INSULIN GLARGINE;NPH insulin (insulin isophane);INSULIN GLULISINE;Regular insulin
14 Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist Completed NCT02738151 Phase 4 INSULIN GLARGINE (U300);Insulin degludec;GLP-1 receptor agonist;Glimepiride;Metformin
15 Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan Completed NCT01758380 Phase 4 Vildagliptin;Gliclazide;Metformin;Placebo to Gliclazide;Placebo to Vildagliptin
16 Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia Completed NCT01013402 Phase 4 Human insulin;Human Insulin
17 Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure Completed NCT01117350 Phase 4 Insulin glargine;Liraglutide;Metformin
18 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
19 Initiation and Titration of Amaryl Completed NCT01144728 Phase 4 GLIMEPIRIDE + METFORMIN
20 Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study Completed NCT01121835 Phase 4 INSULIN GLARGINE;INSULIN GLULISINE;PREMIXED INSULIN
21 The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes Completed NCT00353834 Phase 4 Exenatide;Glargine Insulin
22 Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement Completed NCT00354939 Phase 4 Insulin glargine
23 Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients Completed NCT00957060 Phase 4 GLIMEPIRIDE (HOE490);SITAGLIPTIN
24 Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions Completed NCT01283425 Phase 4
25 Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs Completed NCT01203111 Phase 4 INSULIN GLARGINE;INSULIN GLULISINE
26 Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment Completed NCT00949442 Phase 4 Insulin Glargine (HOE901) [Lantus];Glimepiride;human insulin [NPH]
27 Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients Completed NCT00751114 Phase 4 Insulin Glargine;Sitagliptin;Metformin
28 Metformin and Oral Contraceptives in PCOS Completed NCT00451568 Phase 4 Metformin;Desorelle
29 Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment Completed NCT02967237 Phase 4 insulin glargine (U300)
30 Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs Completed NCT00819741 Phase 4 repaglinide;metformin;repaglinide
31 Insulin Glargine in Type 2 Diabetes Mellitus Completed NCT00272077 Phase 4 Insuline glargine
32 Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes Completed NCT01630369 Phase 4 insulin human (HR1799)
33 Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2) Completed NCT00659477 Phase 4 insulin glargine
34 Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment Completed NCT01076842 Phase 4 Insulin-Levemir;Exenatide-Bayetta;Insulin-Levemir and Exenatide-Bayetta
35 Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin Completed NCT00693771 Phase 4 Insulin Glargine
36 Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin) Completed NCT00708578 Phase 4 Glimepiride;Metformin;Insulin Glargine
37 The Effect of Metformin in Overweight Patients With Dysregulated Type 1 Diabetes Mellitus Completed NCT00145379 Phase 4 Tablet Metformin 500 mg;Placebo
38 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
39 Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients. Completed NCT01649466 Phase 4 LAF237;Protaphane
40 Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA Completed NCT00732524 Phase 4 Glipizide;Glipizide and Glargine
41 Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus Completed NCT00526513 Phase 4 Insulin Glulisine
42 Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes Completed NCT00191282 Phase 4 Insulin lispro;Human insulin isophane suspension (NPH);Insulin glargine;Human insulin isophane suspension;Human insulin 30/70
43 Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects Completed NCT00857870 Phase 4 Metformin;Insulin glargine
44 Safety and Efficacy of Insulin Aspart in Type 2 Diabetes Completed NCT01649570 Phase 4 insulin aspart
45 Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin Completed NCT01099137 Phase 4 Vildagliptin;Sulphonylurea dose-up
46 Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes Completed NCT00276393 Phase 4 Basal insulin
47 A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes Completed NCT00467649 Phase 4 pramlintide acetate (Symlin);rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]);basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
48 Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes Completed NCT00568074 Phase 4 repaglinide;Glurenorm®;Glucobay®
49 Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019) Completed NCT00393705 Phase 4 Insulin Biphasic Aspart 30/70;insulin lispro LM;insulin lispro MM;insulin lispro LM
50 Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes Completed NCT00807092 Phase 4 biphasic insulin aspart 30;biphasic human insulin 30;metformin

Search NIH Clinical Center for Fasting Hypoglycemia

Genetic Tests for Fasting Hypoglycemia

Anatomical Context for Fasting Hypoglycemia

MalaCards organs/tissues related to Fasting Hypoglycemia:

39
Testes, Liver, Pancreas, Pancreatic Islet, Brain, Endothelial, Ovary

Publications for Fasting Hypoglycemia

Articles related to Fasting Hypoglycemia:

(show top 50) (show all 54)
id Title Authors Year
1
Intractable Fasting Hypoglycemia as a Manifestation of Hepatocellular Carcinoma. ( 28785493 )
2017
2
Fasting Hypoglycemia on (18)F-FDG PET/CT Scan. ( 28420855 )
2017
3
Hypothalamic glucagon signaling in fasting hypoglycemia. ( 27084528 )
2016
4
Sexual Dimorphism in Glucose and Lipid Metabolism during Fasting, Hypoglycemia, and Exercise. ( 25964778 )
2015
5
Basal Insulin Use in the Non-Critical Care Setting: Is Fasting Hypoglycemia Inevitable or Preventable? ( 24876599 )
2014
6
The association between fasting hypoglycemia and methylated mercaptopurine metabolites in children with acute lymphoblastic leukemia. ( 24415675 )
2014
7
Aromatic L-amino acid decarboxylase deficiency is a cause of long-fasting hypoglycemia. ( 24037885 )
2013
8
CD36 deficiency predisposing young children to fasting hypoglycemia. ( 20947105 )
2011
9
Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion. ( 18635551 )
2008
10
Poor specificity of low growth hormone and cortisol levels during fasting hypoglycemia for the diagnoses of growth hormone deficiency and adrenal insufficiency. ( 18694902 )
2008
11
Increased glucose tolerance and reduced adiposity in the absence of fasting hypoglycemia in mice with liver-specific Gs alpha deficiency. ( 16239968 )
2005
12
Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus. ( 15031319 )
2004
13
The diagnosis of fasting hypoglycemia due to an islet-cell tumor obscured by a highly specific insulin assay. ( 12679423 )
2003
14
Fasting hypoglycemia in solitary fibrous tumor of the peritoneum: a diagnostic clue for an emergent situation. ( 15290507 )
2003
15
Protein-sensitive and fasting hypoglycemia in children with the hyperinsulinism/hyperammonemia syndrome. ( 11241047 )
2001
16
Fasting hypoglycemia is common during maintenance therapy for childhood acute lymphoblastic leukemia. ( 11241057 )
2001
17
Two cases of large solitary fibrous tumors of the pleura associated with fasting hypoglycemia. ( 11372615 )
2001
18
Anti-insulin receptor autoantibodies in a patient with type B insulin resistance and fasting hypoglycemia. ( 11450502 )
2000
19
Primary malignant fibrous histiocytoma of the lung: IGF-II producing tumor induces fasting hypoglycemia. ( 11149628 )
2000
20
Severe and recurrent fasting hypoglycemia due to growth hormone deficiency? ( 10493328 )
1999
21
[Peripheral plasma corticotropin-releasing hormone (CRH) in an aged patient with fasting hypoglycemia associated with an insufficient secretion of insulin: an implication of plasma CRH in glucose metabolism]. ( 7556777 )
1995
22
Mechanisms of fasting hypoglycemia and concomitant insulin resistance in insulinoma patients. ( 8446044 )
1993
23
A practical approach to fasting hypoglycemia. ( 1545839 )
1992
24
Effect of insulin-induced and fasting hypoglycemia on perinatal hypoxic-ischemic brain damage. ( 1542541 )
1992
25
A glucose reduction challenge in the differential diagnosis of fasting hypoglycemia: a two-center study. ( 2407752 )
1990
26
Adult nesidioblastosis. An unusual cause of fasting hypoglycemia. ( 2729774 )
1989
27
Hyperinsulinemia due to impaired insulin clearance associated with fasting hypoglycemia and postprandial hyperglycemia: an analysis of a patient with antiinsulin receptor antibodies. ( 2668322 )
1989
28
Idiopathic fasting hypoglycemia in an adult. ( 3812525 )
1987
29
Prolonged fasting hypoglycemia due to insulin antibodies in patient with non-insulin-dependent diabetes mellitus: effect of insulin withdrawal on insulin-antibody-binding kinetics. ( 3582076 )
1987
30
Fasting hypoglycemia associated with disopyramide. ( 6356848 )
1983
31
Fasting hypoglycemia. ( 6870429 )
1983
32
Hypoketonemia and age-related fasting hypoglycemia in growth hormone deficiency. ( 6341760 )
1983
33
Fasting hypoglycemia in adults. ( 6279046 )
1982
34
Clinicopathologic Conference. Intra-abdominal malignancy and fasting hypoglycemia. ( 7124779 )
1982
35
Fasting hypoglycemia resulting from hepatic carnitine palmitoyl transferase deficiency. ( 7014807 )
1981
36
Fasting hypoglycemia secondary to disopyramide therapy. Report of two cases. ( 6785461 )
1981
37
Glycemic response to glucagon during fasting hypoglycemia: an aid in the diagnosis of hyperinsulinism. ( 7351590 )
1980
38
Spontaneous fasting hypoglycemia: basal levels of plasma free fatty acids and glycerol, blood ketone bodies, serum cholesterol and plasma growth hormone. ( 668979 )
1978
39
Fasting hypoglycemia in a pup. ( 730606 )
1978
40
Fasting hypoglycemia in a pup. ( 689974 )
1978
41
An insulinoma without fasting hypoglycemia. ( 188337 )
1976
42
Hyperinsulinism in infancy: diagnosis by demonstration of abnormal response to fasting hypoglycemia. ( 940710 )
1976
43
Fasting hypoglycemia. A clinicopathologic conference from Veterans Administration Hospital Hines, Illinois. ( 177961 )
1976
44
The diagnosis of insulinomas and other causes of fasting hypoglycemia. ( 179928 )
1976
45
Fasting hypoglycemia in adults. ( 176582 )
1976
46
Hypoglycemia: Clinical implications. Part II: Fasting hypoglycemia. ( 1115649 )
1975
47
Fasting hypoglycemia. Diazoxide as a test for endogenous insulin release. ( 4373514 )
1974
48
Fasting hypoglycemia, hypercalcemia and hyperprolactinemia. Multiple endocrine neoplasia, type 1? ( 4372884 )
1974
49
Control of refractory fasting hypoglycemia in a patient with suspected insulinoma with diphenylhydantoin. ( 4358644 )
1974
50
Fasting hypoglycemia. ( 4355740 )
1973

Variations for Fasting Hypoglycemia

Expression for Fasting Hypoglycemia

Search GEO for disease gene expression data for Fasting Hypoglycemia.

Pathways for Fasting Hypoglycemia

Pathways related to Fasting Hypoglycemia according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.57 GYS1 GYS2 IGF1 INSR
2
Show member pathways
12.29 GYS1 GYS2 IGF1 IGF2 INSR
3
Show member pathways
12.1 GYS1 IGF1 IGF2
4
Show member pathways
11.84 GYS1 GYS2 INSR
5 11.71 CRH GLP1R POMC
6
Show member pathways
11.48 GYS1 GYS2 POMC
7
Show member pathways
11.44 CD36 GYS1 GYS2 IGF1 INSR
8
Show member pathways
11.29 CD36 GYS1 GYS2 INSR
9 11.09 IGF1 INSR
10 11.07 GYS1 GYS2
11 10.94 GYS1 INSR
12
Show member pathways
10.87 IGF1 IGF2
13 10.73 IGF1 IGF2
14 10.1 CRH POMC

GO Terms for Fasting Hypoglycemia

Biological processes related to Fasting Hypoglycemia according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.78 CRH IGF1 IGF2 INSR
2 positive regulation of protein phosphorylation GO:0001934 9.63 CRH IGF2 INSR
3 platelet degranulation GO:0002576 9.54 CD36 IGF1 IGF2
4 positive regulation of glucose import GO:0046326 9.52 IGF1 INSR
5 positive regulation of activated T cell proliferation GO:0042104 9.51 IGF1 IGF2
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.5 CD36 IGF1 IGF2
7 activation of protein kinase B activity GO:0032148 9.49 IGF1 INSR
8 adrenal gland development GO:0030325 9.43 CRH INSR
9 glycogen biosynthetic process GO:0005978 9.43 ACADM GYS1 GYS2
10 positive regulation of glycolytic process GO:0045821 9.4 IGF1 INSR
11 positive regulation of mitotic nuclear division GO:0045840 9.33 IGF1 IGF2 INSR
12 positive regulation of MAPK cascade GO:0043410 9.26 CD36 IGF1 IGF2 INSR
13 positive regulation of glycogen biosynthetic process GO:0045725 8.8 IGF1 IGF2 INSR

Molecular functions related to Fasting Hypoglycemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.37 IGF1 IGF2
2 glycogen synthase activity, transferring glucose-1-phosphate GO:0061547 9.26 GYS1 GYS2
3 hormone activity GO:0005179 9.26 CRH IGF1 IGF2 POMC
4 glycogen (starch) synthase activity GO:0004373 9.16 GYS1 GYS2
5 neuropeptide hormone activity GO:0005184 9.02 CRH
6 insulin-like growth factor receptor binding GO:0005159 8.8 IGF1 IGF2 INSR

Sources for Fasting Hypoglycemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....